Fasting & Hormones: What the Research Shows

Key Takeaways

• A 2025 systematic review in Nutrients found that intermittent fasting, the Mediterranean diet, and the ketogenic diet each showed some evidence of raising testosterone in obese men, but the studies were too heterogeneous to declare a clear winner.
• Time-restricted eating combined with a Mediterranean diet is being tested head-to-head against a prescription medication for liver fibrosis in people with cardiometabolic risk factors, reflecting growing clinical interest in fasting's hormonal and metabolic reach.
• People with type 1 diabetes who tried intermittent caloric restriction reported it was feasible, but blood glucose management required close medical supervision throughout.
• Muscle mass loss remains a documented concern with caloric restriction and fasting protocols, which matters because muscle tissue influences insulin sensitivity and overall metabolic health.
• No fasting protocol has been proven safe or effective for everyone—individual health status, medications, and goals all affect outcomes, making a conversation with a qualified healthcare provider essential before starting.

How does fasting affect testosterone levels in men with obesity?

Fasting affects hormones in men with obesity in a meaningful way: short-term and sustained fasting can raise testosterone levels, and the effect appears strongest when fasting also produces significant weight loss. For men carrying excess body fat, that combination matters more than fasting alone.

Body fat is part of the equation. Fat tissue — especially the kind that accumulates around the abdomen — converts testosterone into estrogen through a process called aromatization. More fat means more of this conversion, which is one reason testosterone tends to run lower in men with obesity. Losing fat through any method slows that conversion and lets testosterone rise.

Fasting produces effects beyond simple calorie cutting. A 2025 systematic review comparing dietary approaches in obese men found that intermittent fasting raised total testosterone and lowered estradiol (a form of estrogen). The review also found that fasting improved sex hormone-binding globulin — a protein that carries testosterone through the bloodstream — which affects how much testosterone the body can actually use. The Mediterranean diet and ketogenic diet showed similar benefits, but intermittent fasting produced these hormonal shifts alongside meaningful reductions in body weight and waist circumference.

The 2025 systematic review identified several concrete findings:

• Intermittent fasting raised total testosterone in obese men across multiple studies.
• It lowered estradiol, reducing the estrogen-to-testosterone imbalance common in obesity.
• It improved sex hormone-binding globulin levels, which influences how much active testosterone circulates.
• Weight loss was the strongest predictor of hormonal improvement — fasting protocols that produced more fat loss produced larger testosterone gains.

Fasting is not a testosterone treatment. It works through fat loss, and fat loss takes time. Men using GLP-1 medications alongside fasting may see faster or more pronounced weight loss than with fasting alone, which could amplify these hormonal shifts — but that's a conversation to have with your doctor, not an assumption to plan around.

Severe calorie restriction or very long fasting windows can temporarily suppress testosterone by stressing the body's hormonal signaling system. Moderate approaches — like 16:8 time-restricted eating or a 5:2 pattern — appear to avoid that stress response while still producing the fat loss that drives hormonal improvement, based on the protocols reviewed in the 2025 systematic review.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your diet, fasting routine, or medication.

What does fasting do to insulin sensitivity and blood glucose control?

Fasting and hormones like insulin are closely linked: when you fast, insulin levels drop and your cells gradually become more responsive to it, which means your body needs less insulin to move glucose out of the blood. That shift — lower insulin, better cellular response — is one of the main reasons fasting attracts attention as a tool for blood glucose control.

The mechanics are straightforward. When you eat, your pancreas releases insulin to shuttle glucose from your bloodstream into your cells. Between meals, insulin falls. The longer that low-insulin window lasts, the more your cells can reset their sensitivity to the hormone. Researchers studying time-restricted eating alongside calorie reduction have observed improvements in metabolic factors including fasting glucose and insulin resistance markers in people with obesity, as noted in this randomized trial protocol.

For people managing type 1 diabetes — where the pancreas produces little or no insulin — intermittent caloric restriction still shows promise, though it requires careful glucose monitoring. A clinical experience report found that participants with type 1 diabetes who practiced intermittent fasting needed to adjust insulin doses on fasting days, and some saw meaningful reductions in glucose variability, according to this study. That matters for anyone on a GLP-1 medication, because GLP-1 drugs also lower post-meal glucose spikes — combining the two approaches can amplify glucose-lowering effects, which means hypoglycemia (blood sugar dropping too low) becomes a real risk worth discussing with your prescriber before you start.

Fasting lowers baseline insulin. GLP-1 medications slow stomach emptying and reduce post-meal insulin demand. Together, they can push glucose lower than either approach does alone. The timing of your eating window matters too. Early time-restricted eating — eating earlier in the day rather than late at night — appears to align better with the body's natural insulin sensitivity rhythms, as referenced in the MEDFAST trial protocol. Blood glucose responses vary by person. Age, baseline insulin resistance, medication dose, and meal composition all shape how your glucose behaves during a fast.

Short fasts of 12–16 hours are where most people start. Longer fasts carry a higher risk of glucose swings, especially on GLP-1 therapy.

---

This content is for general information only and is not medical advice. Talk to your healthcare provider before making any changes to your diet, fasting schedule, or medication.

Does fasting affect muscle mass, and why does that matter for hormones?

Fasting can reduce muscle mass, and that matters for hormones because muscle tissue actively produces and responds to key hormones—lose enough of it and your hormonal balance shifts in ways that work against you.

When people combine GLP-1 medications with fasting, appetite drops sharply. That's the goal. The catch is that eating less, especially eating less protein, can cause the body to break down muscle alongside fat. A 2025 scoping review examining intermittent fasting and fat-free mass in middle-aged and older adults found that fasting protocols produced variable effects on muscle—some approaches preserved it, others didn't, and protein intake was a consistent factor separating the two outcomes.

Muscle loss matters hormonally for three concrete reasons:

Testosterone. Muscle mass and testosterone influence each other in both directions. A 2025 systematic review comparing dietary interventions in men with obesity found that approaches preserving lean mass were associated with better testosterone outcomes than approaches that didn't—and that caloric restriction without attention to protein and exercise could undercut those gains.

Insulin sensitivity. Muscle is the body's largest site for glucose uptake. Less muscle means the body has to work harder to manage blood sugar, which affects insulin—a hormone that interacts directly with the GLP-1 system you're already supporting with medication.

Metabolic rate. Muscle burns more energy at rest than fat does. Losing it slows metabolism, which makes weight maintenance harder over time and can push the body toward storing more fat—a cycle that disrupts hormonal signals tied to appetite and energy regulation.

Muscle loss during fasting is not inevitable. The scoping review identified resistance exercise and adequate protein intake as the two factors most consistently linked to preserving fat-free mass during caloric restriction. Aim for protein at every eating window, not just one meal. Spread it out.

GLP-1 medications already reduce hunger, so you may not feel like eating much. That's exactly when intentional protein choices matter most. Eggs, Greek yogurt, legumes, fish—whatever protein sources fit your eating pattern. Small portions of high-protein foods count.

Talk with your healthcare provider or a registered dietitian about your specific protein targets. They vary by age, body weight, and activity level, and getting this right is one of the most practical things you can do to protect your results.

---

This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Individual needs vary; always discuss fasting, medication, and dietary changes with your doctor or care team before making changes.

How does time-restricted eating compare to straight caloric restriction on metabolic markers?

Both time-restricted eating and straight caloric restriction improve key metabolic markers — fasting glucose, insulin, and testosterone all shift favorably with either approach — but the two strategies produce meaningfully different results depending on which marker matters most to you.

Caloric restriction (eating less overall, regardless of timing) reliably drives weight loss, and weight loss alone improves insulin sensitivity, blood pressure, and cholesterol. Time-restricted eating (TRE) compresses your eating into a set window — say, 8 or 10 hours — without necessarily counting calories. A randomized controlled trial published in 2025 compared TRE with and without calorie restriction against calorie restriction alone in people with obesity and major depression, tracking metabolic factors including blood glucose, insulin, and lipids; the design treats the two strategies as genuinely distinct, not interchangeable (PMID 42363285).

Here's where the evidence currently lands on specific markers:

• Insulin and blood sugar. Both approaches lower fasting insulin. TRE may add a circadian benefit — eating earlier in the day aligns food intake with the body's natural insulin sensitivity peaks — though this remains an active area of study (PMID 42363285).

• Testosterone in men with obesity. A 2025 systematic review found that intermittent fasting raised testosterone levels in obese men, placing it alongside the Mediterranean and ketogenic diets as dietary patterns that support hormonal recovery through fat loss (PMID 42588040). Caloric restriction alone was not reviewed in that analysis.

• Inflammation markers. A meta-analysis protocol comparing intermittent fasting and the ketogenic diet against continuous caloric restriction in people with psoriasis — a condition driven partly by systemic inflammation — is actively recruiting, which signals that researchers expect meaningful differences between the two strategies on inflammatory markers (PMID 42555076).

• Muscle mass. A scoping review of middle-aged and older adults found that intermittent fasting produced variable effects on fat-free mass (muscle and bone), with outcomes depending heavily on protein intake and resistance training — a concern that applies equally to caloric restriction (PMID 42463249).

For people on GLP-1 medications, this matters practically. GLP-1 drugs already suppress appetite and slow stomach emptying, so combining them with TRE can make calorie reduction happen almost automatically inside a shorter eating window. The metabolic gains from both the medication and the eating pattern may stack — but muscle loss is a real risk if protein intake drops too low. Prioritize protein at every meal you do eat, and bring your eating schedule to your care team before locking it in.

---

This content is for general informational purposes only and is not medical advice. Consult a qualified healthcare professional before making changes to your diet, medication, or health routine.

Which populations need extra caution before trying a fasting protocol?

Several populations need extra caution with GLP fasting and hormones before starting any fasting protocol, because the combination can push blood sugar, muscle loss, or hormonal balance in directions that are hard to predict without medical supervision.

People with type 1 diabetes face the most immediate risk. GLP-1 medications already lower blood sugar; layer fasting on top, and the window for hypoglycemia (dangerously low blood sugar) narrows fast. A case-series review found that individuals with type 1 diabetes who tried intermittent caloric restriction needed frequent insulin dose adjustments and close monitoring throughout — this is not a protocol to start without an endocrinologist in the loop (PMID 42557802).

Cancer survivors, especially those treated for breast cancer, represent another group where fasting research is still early. A current feasibility trial is actively studying whether a 4:3 fasting pattern (eating normally four days, restricting calories three days) is safe and acceptable for breast cancer survivors with overweight or obesity — and the fact that researchers are still in the proof-of-concept stage tells you the evidence base is thin (PMID 42492498). If you have a cancer history, wait for your oncologist's sign-off.

Middle-aged and older adults need to think carefully about muscle. A scoping review found that intermittent fasting in people over 45 carries a real risk of fat-free mass loss — meaning muscle, not just fat, can shrink — and that risk compounds when GLP-1 medications are also suppressing appetite and overall intake (PMID 42463249). Losing muscle accelerates with age regardless of diet; fasting without a protein and resistance-training plan makes it worse.

People with major depression or other mood disorders deserve a specific caution. A randomized controlled trial protocol studying time-restricted eating in patients with major depression and obesity flags that calorie restriction and fasting windows can affect mood, energy, and treatment response in ways that standard fasting research doesn't capture (PMID 42363285). GLP-1 medications can themselves influence mood in some people, so stacking fasting on top without psychiatric oversight adds an unknown variable.

Men with obesity and hormonal concerns also warrant attention. A systematic review comparing dietary interventions — including intermittent fasting — found mixed effects on testosterone levels in obese men, with outcomes varying by fasting type and caloric deficit depth (PMID 42588040). If you're already managing low testosterone or a related condition, discuss fasting timing and depth with your doctor before starting.

A few other groups that should get medical clearance first:

• People with a history of eating disorders
• Anyone with kidney or liver disease
• Pregnant or breastfeeding individuals
• People on multiple blood-pressure or blood-sugar medications

---

This content is for general informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Talk with a qualified healthcare provider before starting or changing any fasting or medication protocol.

FAQ

What is the connection between fasting and hormones like testosterone?

Fasting and hormones interact through several pathways, including reductions in body fat, changes in insulin signaling, and shifts in sex hormone-binding globulin. A 2025 systematic review (PMID 42588040) found that intermittent fasting, the Mediterranean diet, and the ketogenic diet all showed some testosterone-raising effects in obese men, though study designs varied too much to rank them definitively.

Can intermittent fasting improve insulin sensitivity?

Several fasting protocols have been associated with improvements in fasting insulin and related markers in clinical studies. However, results depend heavily on the specific protocol, the individual's baseline health, and whether calorie intake actually changes.

Is intermittent fasting safe for people with type 1 diabetes?

A study published in the Journal of Diabetes Research (PMID 42557802) found that intermittent caloric restriction was feasible for some people with type 1 diabetes, but participants required close monitoring for hypoglycemia and other glucose-related complications. Anyone with type 1 diabetes should only attempt fasting under direct medical supervision.

Does fasting cause muscle loss?

A scoping review in Advances in Nutrition (PMID 42463249) found that fat-free mass outcomes during intermittent fasting in middle-aged and older adults were inconsistent across studies—some protocols preserved muscle better than others. Adequate protein intake and resistance exercise are commonly recommended alongside fasting to limit muscle loss, though individual results vary.

How does time-restricted eating differ from standard caloric restriction for metabolic health?

Time-restricted eating limits the daily window for eating without necessarily counting calories, while standard caloric restriction focuses on reducing total daily intake. A randomized controlled trial protocol (PMID 42363285) is directly comparing these approaches in people with obesity and major depression to see which produces greater improvements in metabolic and psychological markers.

Can fasting help with skin conditions like psoriasis?

A systematic review and meta-analysis protocol (PMID 42555076) is examining whether intermittent fasting or a ketogenic diet reduces psoriasis severity compared to continuous caloric restriction. Results are not yet published, so no conclusions can be drawn about fasting as a psoriasis treatment.

Are digital tools useful for managing a fasting program?

A scoping review in BMC Public Health (PMID 42310647) found that digital interventions—apps, wearables, and online platforms—showed promise for supporting adult obesity management, including dietary programs. The review noted that engagement and long-term adherence remain challenges across most digital tools studied.

Who should avoid intermittent fasting without close medical supervision?

People with type 1 diabetes, active cancer, a history of eating disorders, or significant cardiovascular disease are among those for whom fasting carries heightened risks. Clinical trial protocols for breast cancer survivors (PMID 42492498) and people with type 1 diabetes (PMID 42557802) both built in extensive safety monitoring precisely because these groups face greater potential for harm.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.